Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guyatt

Showing results (131-140 of 2,131) with videos related to

Pageof 214
Sort By:
Clinical Chemistry|February 17, 2019
Measurement of Treatment Effects Requires Instruments Responsive to Change Based on the Minimal Important DifferenceBradley C Johnston, Gordon H Guyatt
Journal of Clinical Epidemiology|October 9, 2022
Evidence, values, and masks for control of COVID-19: 2 years laterBenjamin Djulbegovic, Iztok Hozo, Gordon Guyatt
Tropical Medicine & International Health : TM & IH|July 10, 1998
An investigation into the interaction between drug efficacy and drug price of praziquantel in determining the cost-effectiveness of school-targeted treatment for Schistosoma mansoni using a population dynamic modelH L Guyatt, M S Chan
Chest|October 1, 1987
Rigorous evaluation. Greater need than everG H Guyatt, M T Newhouse
JAMA Internal Medicine|September 8, 2018
A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a TrialReza D Mirza, Gordon H Guyatt
International Journal of Technology Assessment in Health Care|December 11, 1984
The ethics and feasibility of randomized trials of diagnostic technology: a replyG H Guyatt, M F Drummond
ACP Journal Club|February 7, 2002
Review: albumin administration is not associated with excess mortality in acutely ill patientsDeborah J Cook, Gordon H Guyatt
Chest|February 7, 2001
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest PhysiciansJ Hirsh, J Dalen, G Guyatt, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 31, 2002
Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan AfricaH L Guyatt, R W Snow
Pharmacoeconomics|November 3, 1997
Reassessing quality-of-life instruments in the evaluation of new drugsG H Guyatt, R J Jaeschke
Pageof 214

Showing results (131-140 of 2,131) with videos related to

Sort By:
Pageof 214
Clinical Chemistry|February 17, 2019
Measurement of Treatment Effects Requires Instruments Responsive to Change Based on the Minimal Important DifferenceBradley C Johnston, Gordon H Guyatt
Journal of Clinical Epidemiology|October 9, 2022
Evidence, values, and masks for control of COVID-19: 2 years laterBenjamin Djulbegovic, Iztok Hozo, Gordon Guyatt
Tropical Medicine & International Health : TM & IH|July 10, 1998
An investigation into the interaction between drug efficacy and drug price of praziquantel in determining the cost-effectiveness of school-targeted treatment for Schistosoma mansoni using a population dynamic modelH L Guyatt, M S Chan
Chest|October 1, 1987
Rigorous evaluation. Greater need than everG H Guyatt, M T Newhouse
JAMA Internal Medicine|September 8, 2018
A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a TrialReza D Mirza, Gordon H Guyatt
International Journal of Technology Assessment in Health Care|December 11, 1984
The ethics and feasibility of randomized trials of diagnostic technology: a replyG H Guyatt, M F Drummond
ACP Journal Club|February 7, 2002
Review: albumin administration is not associated with excess mortality in acutely ill patientsDeborah J Cook, Gordon H Guyatt
Chest|February 7, 2001
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest PhysiciansJ Hirsh, J Dalen, G Guyatt, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 31, 2002
Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan AfricaH L Guyatt, R W Snow
Pharmacoeconomics|November 3, 1997
Reassessing quality-of-life instruments in the evaluation of new drugsG H Guyatt, R J Jaeschke
Pageof 214